

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395, 38/17	A1	(11) International Publication Number: WO 95/03827 (43) International Publication Date: 9 February 1995 (09.02.95)
(21) International Application Number: PCT/GB93/01614 (22) International Filing Date: 30 July 1993 (30.07.93) (71) Applicant (for all designated States except US): KENNEDY INSTITUTE OF RHEUMATOLOGY [GB/GB]; Sunley Building, 1 Lurgan Avenue, Hammersmith, London W6 8LW (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): TURK, John, Leslie [GB/GB]; 104 Prince George Avenue, London N14 4ST (GB). BAKER, David [GB/GB]; 53A Clifton Road, London SE25 6PX (GB). FELDMANN, Marc [AU/GB]; 2 Church Road, Highgate, London N6 4QT (GB). (74) Agents: HOLDCROFT, James, Gerald et al.; Graham Watt & Co., Riverhead, Sevenoaks, Kent TN13 2BN (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: **METHOD FOR TREATING MULTIPLE SCLÉROSIS**

(57) Abstract

A method for treating multiple sclerosis, through the administration of anti-tumour necrosis factor antibody, of soluble tumour necrosis factor receptor or of a compound capable of blocking tumour necrosis factor production, its effects and/or tumour necrosis factor receptor signal transduction, is disclosed. The method can be used to aid in therapy for humans and other mammals.

AN

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD FOR TREATING MULTIPLE SCLEROSIS

Background

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system which usually presents in the form of recurrent attacks of focal or multifocal neurologic dysfunction. Attacks occur, remit, and recur, seemingly randomly over many years. Remission is often incomplete and as one attack follows another, a stepwise downward progression ensues with increasing permanent deficit.

Clinical disease is associated with blood-brain barrier dysfunction; infiltration of the central nervous system by mononuclear cells, mainly macrophages and T lymphocytes, and serum products; and demyelination (Harris J.O., et al., Ann. Neurol. 29:548 (1991); Kermonde A.G., et al., Brain 113:1477 (1990)).

Presently the nature of autoantigens responsible for multiple sclerosis is not known, nor is the action which triggers the autoimmune response. One popular theory involves the similarity of a viral protein to a self antigen, which results in autoreactive T cells or B cells recognizing a self antigen. Whereas B-lymphocytes produce antibodies, thymus-derived or "T-cells" are associated with cell-mediated immune functions. T-cells recognize antigens presented on the surface of cells and carry out their functions in association with "antigen-presenting" cells.

Currently no practical and efficacious treatments for multiple sclerosis exist. Thus, the development of a method for treating multiple sclerosis would be of immense benefit.

-2-

Summary of the Invention

The present invention relates to a method of treating multiple sclerosis in a mammal. The invention is based on the discovery that tumour necrosis factor (TNF) has a role
5 in the pathogenesis of multiple sclerosis and experimental allergic encephalomyelitis (EAE).

The method comprises administering to a mammal a therapeutically effective amount of an anti-tumour necrosis factor (anti-TNF) antibody which ameliorates the
10 effects of multiple sclerosis. A therapeutically effective amount can be administered in the form of a single dose, or a series of doses separated by intervals of days, weeks or months.

Another method comprises administering to a mammal a
15 therapeutically effective amount of a soluble TNF receptor which ameliorates the effects of multiple sclerosis. A therapeutically effective amount can be administered in the form of a single dose, or a series of doses separated by intervals of days, weeks or months.

20 Another method comprises administering to a mammal a therapeutically effective amount of a compound which is capable of blocking TNF production, its effects and/or tumour necrosis factor receptor signal transduction (anti-TNF compound).

25 The anti-TNF antibody, soluble TNF receptor or anti-TNF compound can be administered together with a pharmaceutically-acceptable vehicle. In a preferred embodiment administration of said antibody, soluble receptor or anti-TNF compound is by injection directly
30 into the central nervous system of a human being. Injection directly into the central nervous system can be

-3-

by injection directly into the lumbar cerebrospinal fluid (intrathecally). In another embodiment administration of said antibody, soluble receptor or anti-TNF compound is intravenously.

- 5 The present invention further relates to a pharmaceutical composition comprised of a pharmaceutically-acceptable carrier and a multiple sclerosis-therapeutically effective amount of anti-TNF antibody which ameliorates the effects of multiple
- 10 sclerosis, soluble TNF receptor which ameliorates the effects of multiple sclerosis or anti-TNF compound.

The benefit of the method of therapy of the subject invention is that it provides an efficacious treatment for multiple sclerosis.

15 Brief Description of the Figures

Figure 1 is a histogram and a graph illustrating the kinetics of weight changes and clinical signs during acute phase chronic relapsing experimental allergic encephalomyelitis (CREAE) induced in Biozzi AB/H mice.

- 20 Figure 2 is a histogram illustrating blood-brain barrier permeability to cells and protein during acute phase CREAE.

Figure 3 is a pair of photographs depicting the immunodetection of TNF α in spinal cord lesions during

25 CREAE.

Figure 4 is a set of photographs depicting the immunofluorescence detection of TNF α on CD4⁺ T lymphocytes, astrocytes and macrophages in spinal cord lesions during CREAE.

-4-

Figure 5 is a graph illustrating the effect on EAE of a single injection of TNF-specific monoclonal antibody.

Figure 6 is a pair of graphs illustrating the inhibition of the development of clinical disease following the injection of TNF-specific monoclonal antibody.

Figure 7 is a pair of graphs showing that anti-TNF, unlike anti-CD4, is not immunosuppressive and does not diminish the proliferative response to the contact sensitizer oxazolone.

Figure 8 is a graph illustrating the dose-dependent inhibition of the progression of clinical EAE following injection of TNF-specific monoclonal antibody directly into the central nervous system.

Figure 9 is a graph illustrating the inhibition of the development of clinical disease following injection of TNF-specific monoclonal antibody directly into the central nervous system.

Figure 10 is a set of three histograms illustrating the individual clinical grades of 5 different animals (in each group) following injection of TNF-specific monoclonal antibody directly into the central nervous system and intraperitoneally.

Figure 11 is a graph illustrating the greater inhibition of EAE by intracerebral injection of a TNF-specific monoclonal antibody or of a soluble human p55-TNF receptor, than by intraperitoneal injection.

Figure 12 is a graph illustrating the inhibition of EAE by systemic injection of a soluble human p55-TNF receptor.

-5-

Detailed Description of the Invention

The present invention concerns the treatment of multiple sclerosis through the administration of anti-TNF antibody, of soluble tumour necrosis factor receptor (TNF-
5 R) or of a compound capable of blocking tumour necrosis factor production, its effects and/or tumour necrosis factor receptor signal transduction (anti-TNF compound). Multiple sclerosis is an autoimmune disease of the central nervous system. The disease is associated with blood-
10 brain barrier dysfunction, infiltration of the central nervous system by mononuclear cells (mainly macrophages and T lymphocytes, and serum products), and demyelination (Harris, J.O., et al., Ann. Neurol. 29:548 (1991); Kermonde, A.G., et al., Brain 113:1477 (1990)). Although
15 CD4⁺ T lymphocytes are involved in the induction of the disease (Mokhtarian, F., et al., Nature 309:356-358 (1984); Waldor, M.K., et al., Science 227:415 (1985)), the effector mechanisms mediating pathogenesis of MS are unknown.

20 Tumour necrosis factor (TNF) has been implicated as an important effector molecule in the pathogenesis of various human diseases and animal models such as gram negative sepsis and rheumatoid arthritis (Tracey, K.J., et al., Nature 330:662 (1987); Brennan, F.M., et al., Lancet
25 2:244 (1989); Williams, R.O., et al., Proc. Natl. Acad. Sci. 89:9784 (1992)).

TNF α is a protein secreted primarily by monocytes and macrophages in response to endotoxin or other stimuli as a soluble homotrimer of 17 kD protein subunits (Smith, R.A.,
30 et al., J. Biol. Chem. 262:6951-6954 (1987)). A membrane-bound 26 kD precursor form of TNF has also been described

-6-

(Kriegler, M., et al., Cell 53:45-53 (1988)). The expression of the gene encoding TNF α is not limited to cells of the monocyte/macrophage family: TNF is also produced by CD4+ and CD8+ peripheral blood T lymphocytes, and by various cultured T and B cell lines (Cuturi, M.C., et al., J. Exp. Med. 165:1581 (1987); Sung, S.-S.J., et al., J. Exp. Med. 168:1539 (1988); Turner, M., et al., Eur. J. Immunol. 17:1807-1814 (1987)).

The term antibody is intended to encompass both polyclonal and monoclonal antibodies. The term antibody is also intended to encompass mixtures of more than one antibody reactive with TNF (e.g., a cocktail of different types of monoclonal antibodies reactive with TNF). The term antibody is further intended to encompass whole antibodies, biologically functional fragments thereof, and chimeric antibodies comprising portions from more than one species, bifunctional antibodies, etc. Biologically functional antibody fragments which can be used are those fragments sufficient for binding of the antibody fragment to TNF.

The chimeric antibodies can comprise portions derived from two different species (e.g., human constant region and murine variable or binding region). The portions derived from two different species can be joined together chemically by conventional techniques or can be prepared as single contiguous proteins using genetic engineering techniques. DNA encoding the proteins of both the light chain and heavy chain portions of the chimeric antibody can be expressed as contiguous proteins.

Monoclonal antibodies reactive with TNF can be produced using somatic cell hybridization techniques

-7-

(Kohler and Milstein, Nature 256:495 (1975)) or other techniques. In a typical hybridization procedure, a crude or purified protein or peptide comprising at least a portion of TNF can be used as the immunogen. An animal is
5 vaccinated with the immunogen to obtain anti-TNF antibody-producing spleen cells. The species of animal immunized will vary depending on the species of monoclonal antibody desired. The antibody producing cell is fused with an immortalizing cell (e.g., myeloma cell) to create a
10 hybridoma capable of secreting anti-TNF antibodies. The unused residual antibody-producing cells and immortalizing cells are eliminated. Hybridomas producing desired antibodies are selected using conventional techniques and the selected hybridomas are cloned and cultured.

15 Polyclonal antibodies can be prepared by immunizing an animal with a crude or purified protein or peptide comprising at least a portion of TNF. The animal is maintained under conditions whereby antibodies reactive with TNF are produced. Blood is collected from the animal
20 upon reaching a desired titre of antibodies. The serum containing the polyclonal antibodies (antisera) is separated from the other blood components. The polyclonal antibody-containing serum can optionally be further separated into fractions of particular types of antibodies
25 (e.g., IgG, IgM).

Murine hybridomas which produce TNF specific monoclonal antibodies are formed by the fusion of mouse myeloma cells and spleen cells from mice immunized against a TNF positive T cells, purified TNF, or other
30 biological preparations comprising TNF. To immunize the mice, a variety of different protocols may be followed.

-8-

For example, mice may receive primary and boosting immunizations of TNF. The fusions are accomplished by standard procedures well known to those skilled in the field of immunology. Kohler and Milstein, Nature, 256:495 (1975) and Kennet, Monoclonal Antibodies (Kennet, et al., Eds. pp. 365, Plenum Press, N.Y., 1980).

The co-transfected resulting clones are then screened for production of antibody reactive with TNF or biological preparations comprising TNF. Those which secrete antibodies of the appropriate reactivity and specificity are cloned to yield a homogeneous cell line secreting anti-TNF antibody.

Human hybridomas which produce monoclonal anti-TNF antibodies are formed from the fusion of B cells from an individual producing anti-TNF antibodies and a human B lymphoblastoid cell line. Alternatively, the fusion partner for the myeloma cell may be a peripheral blood anti-TNF producing lymphocyte. The fusion and screening techniques are essentially the same as those used in the production and selection of murine anti-TNF generating hybridomas.

Also mouse and human hybridomas which produce human anti-TNF antibody may be formed from the fusion of a human antibody producing cell and a murine plasmacytoma cell or a cell which itself is a hybrid having the appropriate properties such as the ability to fuse with human lymphocytes at high frequency; support the synthesis and secretion of high levels of antibody; support the secretion of antibody for prolonged periods of time in culture.

-9-

Another way of forming the anti-TNF producing cell line is by transformation of antibody producing cells. For example, an anti-TNF producing B lymphocyte may be infected and transformed with a virus such as Epstein-Barr virus in the case of B lymphocytes to yield an immortal anti-TNF producing cell. See e.g., Kozbor and Roder, Immunology Today, 4(3):72 (1983). Alternatively the B lymphocyte may be transformed by a transforming gene or transforming gene product.

10 The TNF specific monoclonal antibodies are produced in large quantities by injecting anti-TNF antibody producing hybridomas into the peritoneal cavity of mice or other appropriate animal hosts and, after appropriate time, harvesting the resulting ascitic fluid which
15 contains a high titre of antibody and isolating the monoclonal anti-TNF antibody therefrom. Allogeneic or xenogeneic hybridomas should be injected into immunosuppressed, irradiated or athymic nude mice. Alternatively, the antibodies may be produced by culturing
20 anti-TNF producing cells in vitro and isolating secreted monoclonal anti-TNF antibodies from the cell culture medium.

Chimeric anti-TNF antibodies are produced by cloning DNA segments encoding the heavy and light chain variable
25 regions of a non-human antibody specific for TNF and joining these DNA segments to DNA segments encoding human heavy and light chain constant regions to produce chimeric immunoglobulin encoding genes. The fused gene constructs coding for the light and heavy chains are assembled in or
30 inserted into expression vectors. The genes are co-transfected into a lymphoid recipient cell (e.g., a

-10-

myeloma cell) where the immunoglobulin protein can be synthesized, assembled and secreted. The transfected recipient cells are cultured and the expressed immunoglobulins are collected.

- 5 A more detailed description of anti-TNF antibodies and their use in treatment of disease is contained in the following references, the teachings of which are incorporated by reference: U.S. Application No. 07/943,852, filed September 11, 1992; Rubin, et al., EPO
- 10 Patent Publication 0218868, April 22, 1987; Yone, et al., EPO Patent Publication 0288088, October 26, 1988; Liang, C.-M., et al., Biochem. Biophys. Res. Comm. 137:847 (1986); Meager, A., et al., Hybridoma 6:305 (1987); Fendly, et al., Hybridoma 6:359 (1987); Bringman, T.S., et
- 15 al., Hybridoma 6:489 (1987); Hirai, M., et al., J. Immunol. Meth. 96:57 (1987); Moller, A., et al., Cytokine 2:162 (1990); Mathison, J.C., et al., J. Clin. Invest. 81:1925 (1988); Beutler, B., et al., Science 229:869 (1985); Tracey, K.J., et al., Nature 330:662 (1987);
- 20 Shimamoto, Y., et al., Immunol. Lett. 17:311 (1988); Silva, A. T., et al., J. Infect. Dis. 162:421 (1990); Opal, S.M., et al., J. Infect. Dis. 161:1148 (1990); Hinshaw, L.B., et al., Circ. Shock 30:279 (1990).

- Particular preferred antibodies are TNF-specific
- 25 antibodies with a high binding affinity, i.e., with an association constant K of at least 10^8 litres per mole. The association constant K can be determined by equilibrium dialysis as described in Kuby, J., Immunology, W.H. Freeman & Co., New York, 1992, pp. 122-124.

- 30 A more detailed description of antibody affinity and the association constant K is contained in the following

-11-

references, the teachings of which are incorporated by reference: Kuby, J., Immunology, W.H. Freeman & Co., New York, 1992, pp. 122-124; Hood, L.E., et al., Immunology, Second Edition, The Benjamin/Cummings Publishing Co.,
5 Menlo Park, CA, 1984, pp. 58-60; Abbas, A.K., et al., Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia, 1991, pp. 53-54.

The term soluble receptor is intended to encompass cloned soluble whole receptors, biologically functional
10 fragments thereof, and cloned soluble chimeric receptors. The term soluble receptor is further intended to include all cloned soluble molecules which neutralize tumour necrosis factor (i.e., bind to TNF) or which inhibit TNF biological activity. Biologically functional receptor
15 fragments which can be used are those fragments sufficient for binding of the tumour necrosis factor or those fragments capable of inhibiting TNF biological activity.

Cloned soluble chimeric receptors include those molecules capable of binding TNF which are made by fusion
20 of a portion of a TNF receptor to at least one immunoglobulin heavy or light chain. The portion of the TNF receptor present in the cloned chimeric receptor consists of at least a portion of the extracellular region of the TNF receptor. Other types of fusions which result
25 in molecules that are capable of binding TNF are also included.

The chimeric receptors can comprise portions derived from two different species (e.g., extracellular domain of human TNF receptor and C_H2 through C_H3 domains of murine
30 IgG1 heavy chain). The portions derived from two different species can be joined together chemically by

-12-

conventional techniques or can be prepared as single contiguous proteins using genetic engineering techniques as described in Peppel, K., et al., J. Exp. Med. 174:1483-1489 (1991). DNA encoding both portions of the chimeric
5 receptor can be expressed as contiguous chimeric receptor proteins.

The chimeric receptors can comprise two portions derived from the same species (e.g., extracellular domain of human TNF receptor and constant domains of human IgG
10 heavy chain). The two portions can be joined together chemically by conventional techniques or can be prepared as single contiguous proteins using genetic engineering techniques as described in Lesslauer, W., et al., Eur. J. Immunol. 21:2883-2886 (1991), and Ashkenazi, A., et al.,
15 Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991). DNA encoding both portions of the chimeric receptor can be expressed as contiguous chimeric receptor proteins.

Other chimeric TNF receptor compositions are possible and can be employed in the subject invention. (See e.g.,
20 Scallon, B., et al., U.S. Application No. 08/010,406, filed January 29, 1993). A more detailed description of chimeric TNF receptors and their ability to bind TNF is contained in the following references, the teachings of which are incorporated by reference: Scallon, B., et al.,
25 U.S. Application No. 08/010,406, filed January 29, 1993; Peppel, K., et al., J. Exp. Med. 174:1483 (1991); Lesslauer, W., et al., Eur. J. Immunol. 21:2883 (1991); Ashkenazi, A., et al., Proc. Natl. Acad. Sci. USA 88:10535 (1991).

30 Compounds and ligands capable of blocking TNF production, its effects and/or tumour necrosis factor

-13-

receptor signal transduction but which are not receptors can also be employed in the subject invention. Such compounds include, but are not limited to, peptides, anti-TNF drugs and anti-TNF signal transduction compounds.

5 Anti-TNF antibodies, soluble TNF receptors or anti-TNF compounds are useful if, upon administration to the host in an effective amount, they ameliorate the clinical symptoms or causes of multiple sclerosis. The symptoms or causes are ameliorated if they are significantly reduced
10 or eliminated.

It is desirable to administer the anti-TNF antibodies, soluble TNF receptors, and anti-TNF compounds employed in the subject invention directly to the central nervous system. However, the existence of the blood-brain
15 barrier limits the free passage of many types of molecules from the blood to cells of the central nervous system (e.g., potentially useful and therapeutic agents such as anti-TNF antibodies and soluble TNF receptors). During the active phase of inflammatory diseases such as MS and
20 EAE, blood brain leakage is known to occur and will permit entry of anti-TNF antibody, soluble TNF receptors or anti-TNF compounds to the central nervous system. Nevertheless, there are several techniques that either physically break through the blood-brain barrier or
25 circumvent it to deliver therapeutic agents. Examples of these techniques include intrathecal injections, surgical implants, and osmotic techniques. In addition, the permeability of the blood-brain barrier to anti-TNF antibodies, soluble TNF receptors, and anti-TNF compounds
30 can be increased by administering a bradykinin agonist of blood-brain permeability (e.g., N-acetyl [Phe⁸(CH₂-NH)Arg⁹]

-14-

bradykinin). A more detailed description of these techniques that either physically break through the blood-brain barrier or circumvent it are contained in Malfroy-Camine, United States Patent No. 5,112,596, May 12, 1992, the teachings of which are incorporated by reference.

A preferred embodiment for the administration of the antibodies, soluble receptors and anti-TNF compounds is by intrathecal injection, i.e., directly into the cerebrospinal fluid by puncturing the membranes surrounding the central nervous system. Puncturing of the membranes surrounding the central nervous system is usually by lumbar puncture. Sustained dosages of agents directly into the cerebrospinal fluid can be attained by the use of infusion pumps that are implanted surgically.

Another embodiment for the administration of anti-TNF antibodies, soluble TNF receptors, and anti-TNF compounds is by injection directly into the lumbar cerebrospinal fluid (intrathecally) or by injection intravenously. Other methods and modes of administration can also be employed.

The pharmaceutically-acceptable form in which the anti-TNF antibody, soluble TNF receptor, or anti-TNF compound is administered will depend, at least in part, on the route by which it is administered. For example, in the case of administration by injection, the anti-TNF antibody, soluble TNF receptor, or anti-TNF compound can be formulated with conventional pharmaceutically-acceptable vehicles into pharmaceutical compositions in the usual way for that route of administration. Such vehicles are inherently nontoxic and nontherapeutic.

-15-

A therapeutically effective amount of anti-TNF antibody, soluble TNF receptor, or anti-TNF compound is that amount necessary to significantly reduce or eliminate symptoms associated with multiple sclerosis. An efficacious amount of anti-TNF antibody for mice is in the range of 150 μ g - 1 mg/injection. Therefore, a reasonable and preferred therapeutically effective amount of anti-TNF antibody for humans is in the range of 0.1 - 50 mg/kg/dose. Similarly, a preferred therapeutically effective amount of soluble TNF receptor for mice is in the range of 15 - 150 μ g/injection. Therefore, a reasonable and preferred therapeutically effective amount of soluble TNF receptor for humans is in the range of 0.1 - 10 mg/kg/dose. The therapeutically effective amount will be determined on an individual basis and will be based, at least in part, on consideration of the individual's size, the severity of symptoms to be treated, the result sought, etc. Thus, the therapeutically effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.

The therapeutically effective amount can be administered in the form of a single dose, or a series of doses separated by intervals of days, weeks or months. Once the therapeutically effective amount has been administered, a maintenance amount of anti-TNF antibody, of soluble TNF receptor, or of anti-TNF compound can be administered. A maintenance amount is the amount of anti-TNF antibody, soluble TNF receptor, or anti-TNF compound necessary to maintain the reduction or elimination of symptoms achieved by the therapeutically effective dose.

-16-

The maintenance amount can be administered in the form of a single dose, or a series of doses separated by intervals of days, weeks or months. Like the therapeutically effective amount, the maintenance amount will be
5 determined on an individual basis.

Other anti-inflammatory or anti-immune drugs, such as methotrexate or cyclosporin A, or antibodies, such as anti-CD4 antibodies, can be administered in conjunction with the anti-TNF antibody, the soluble TNF receptor, or
10 the anti-TNF compound. (See e.g., Feldmann, M., et al., U.S. Application No. 07/958,248, filed October 8, 1992).

The method of the present invention can be used to treat multiple sclerosis or any related disease in any mammal. In a preferred embodiment, the method is used to
15 treat multiple sclerosis in human beings.

Described herein is work which illustrates the effect of anti-TNF antibody and soluble TNF-R IgG fusion protein in EAE, the results of which indicate that blocking TNF biological activity or other TNF effects, or blocking TNF
20 receptor signal transduction is useful in treating MS.

The experiments described herein utilizes EAE as an experimental model of the human demyelinating disease multiple sclerosis. Chronic relapsing EAE is an autoimmune demyelinating disease of the central nervous
25 system used as an experimental model of MS.

This mouse model of induced EAE has similarities to human MS in its clinical signs. In both EAE and MS, clinical disease is associated with blood-brain barrier (BBB) dysfunction, infiltration of central nervous system
30 by mononuclear cells (mainly macrophages and T lymphocytes, and serum products), and demyelination

-17-

(Baker, D., et al., J. Neuroimmunol. 28:261 (1990); Butter, C., et al., J. Neurol. Sci. 104:9 (1991); Harris J.O., et al., Ann. Neurol. 29:548 (1991); Kermonde A.G., et al., Brain 113:1477 (1990)). Thus, the mouse model
5 serves as a good approximation to human disease.

To facilitate the determination of whether TNF is important in the pathogenesis of neuroimmunological diseases such as EAE and MS, a TNF-specific monoclonal antibody (TN3.19.12) was administered as described in
10 Examples 5, 6 and 7 during actively-induced EAE (Example 1), shortly before (1-2 days) pre-clinical weight loss, when BBB dysfunction and infiltration of the central nervous system became apparent (Example 2) (Butter, C., et al., J. Neurol. Sci. 104:9 (1991)), and during active
15 clinical disease when neurological signs were manifested (Example 1), and a soluble human TNF receptor (human p55 TNF-R) was administered as described in Examples 8 and 9 during actively-induced EAE, shortly following the onset of clinical signs. As described in Examples 5, 6, 7, 8
20 and 9, TNF immunotherapy was found to inhibit the progression of chronic relapsing EAE, and thus has implications for the therapeutic strategies in the human disease multiple sclerosis.

As described in Example 2, the disease episodes of
25 chronic relapsing EAE are associated with BBB dysfunction (Figure 2) and marked cellular infiltration of the central nervous system (Baker, D., et al., J. Neuroimmunol. 28:261 (1990); Butter, C., et al., J. Neurol. Sci. 104:9 (1991)). As described in Examples 1, 2 and 3, these parameters
30 which are modulated by anti-TNF antibody (Table 2), correlated with progressive weight loss which occurs

-18-

shortly before the detection of clinical neurological deficit (Figure 1).

The ability of TNF to augment clinical disease (Kuroda, Y., et al., J. Neuroimmunol. 34:159-164 (1991)) and induce the production of other proinflammatory cytokines (Beutler, B., et al., Science 229:869 (1985); Brennan, F.M., et al., Lancet 2:244 (1989)), and the inhibition of EAE following TNF-neutralization as described herein, implicates an important proinflammatory role for TNF in the pathogenesis of EAE. As described in Examples 5, 6 and 7, clinical EAE developed following the cessation of antibody therapy, indicating that TNF immunotherapy is not exerting an effect through generalized immunosuppression.

As described in Example 4, in contrast to the immunosuppressive action of CD4-specific monoclonal antibody on EAE and T cell proliferation, inhibition of TNF activity exhibited minimal effects on T proliferative responses (Figure 7), indicating that TNF-directed immunotherapy targets effector cell function rather than the induction of disease and consistent with the inability of in vitro treatment of encephalitogenic cells to inhibit adoptive transfer of disease (Selmaj, K., et al., Ann. Neurol. 30:694 (1991)). Therefore the relative timing of antibody administration is important for an inhibitory effect to be observed. For example, in contrast to the inhibitory effect of multiple doses observed when treatment was administered during the anticipated development of disease (Table 1), similar treatment (3 x 250 μ g TN3.19.12 injected intraperitoneally) terminated prior to development of anticipated clinical disease

-19-

failed to prevent the development of clinical EAE (8 of 8 affected with a mean group score of 3.3 ± 0.5).

As described in Examples 5, 6 and 7, although systemic administration of neutralizing TNF antibodies inhibited EAE (Figures 6, 9 and 10), significantly increased benefit was observed when TNF was administered directly into the central nervous system (Figures 9 and 10), indicating that the majority of TNF activity is generated within the central nervous system. Antibodies have a limited potential to cross the intact blood brain barrier (Hafler, D.A., *et al.*, Ann. Neurol. 21:89 (1987)). However, if TNF-specific monoclonal antibody is administered systemically to multiple sclerosis patients, increased targeting of antibody into the central nervous system would occur when blood-brain barrier dysfunction is present, which frequently occurs in clinically silent MS (Harris, J.O., *et al.*, Ann. Neurol. 29:548 (1991); Kermonde, A.G., *et al.*, Brain 113:1477 (1990)), as well as during clinical episodes.

The Examples described herein demonstrate the important role of TNF in the demyelinating disease EAE, an experimental model of MS, thereby indicating that TNF is a suitable target for immune intervention and indicating a method for treating multiple sclerosis. Further, the work described herein indicate the advantages of administering TNF antibodies, soluble TNF receptors or anti-TNF compounds directly into the central nervous system.

In addition, unlike previous studies using anti-TNF in EAE where the effect on EAE was limited only if the antibody was given before the onset of clinical manifestations, i.e., prophylactically (Selmaj, K., *et*

-20-

al., Ann. Neurol. 30:694 (1991); Ruddle, N., J. Exp. Med. 172:1193 (1990)), the work described herein demonstrate therapy after the onset of clinical manifestations, a situation which is relevant to treating multiple sclerosis in human beings.

The present invention is further illustrated by the following Examples, which are not to be limiting in any way.

Example 1: Induction of Experimental Allergic Encephalomyelitis

Inbred Biozzi AB/H (H-2^{dq1}) mice were injected with 1 mg of spinal cord homogenate (SCH) emulsified with Freund's incomplete adjuvant supplemented with 60 µg mycobacteria (Mycobacteria tuberculosis H37Ra and M. butyricum in an 8 to 1 ratio) on days 0 and 7 as described previously (Baker, D., et al., J. Neuroimmunol. 28:261 (1990)). From day 11 (D11) post-inoculation (p.i.) onwards the mice were weighed and checked for clinical signs (Figure 1). These signs were graded as follows: 0 = normal, 1 = totally limp tail, 2 = impaired righting reflex, 3 = partial hindlimb paralysis and 4 = complete hindlimb paralysis. Neurological signs of lower severity than typically observed were scored 0.5 lower than the grade indicated (Baker, D., et al., J. Neuroimmunol. 28:261 (1990)).

Clinical phases of acute EAE have been described previously (Allen, S.J., et al., Cell Immunol. 146:335 (1993)). Briefly weight loss (WL), initially of more than 1.5 grammes/day, occurred generally on days 13-15 p.i. This was followed by the onset of signs (OS), manifested

-21-

by a flaccid tail, on days 15-17 p.i. and by days 17-19 p.i. animals were experiencing acute phase paralysis (AP), grade 3-4. Paralyzed animals (grade 3-4) eventually exhibited a weight gain (WG) and clinical signs began to abate during the post-acute (PA) period with animals showing grade 2-1 disease, generally by days 21-23 p.i. (Figure 1). Typically by day 24 p.i. animals have entered a period of clinical and histological remission (Baker, D., et al., J. Neuroimmunol. 28:261 (1990)) when the central nervous system is again relatively impermeable to the entry of lymphocytes and serum proteins (Butter, C., et al., J. Neurol. Sci. 104:9 (1991)).

Figure 1 illustrates the kinetics of weight changes and clinical signs during acute phase chronic relapsing experimental allergic encephalomyelitis (CREAE) induced in Biozzi AB/H mice. The data depicted shows that active clinical disease correlates with progressive weight changes. Each bar on the histogram represents the mean percentage loss of body weight, relative to that expressed 3 days prior to the onset of clinical disease and each circle on the graph represents the mean clinical score relative to the day of onset of clinical disease on day 0. The data represents the mean \pm SEM of 13 individual mice. The relative times of the different disease phases are indicated. Abbreviations correspond to the following phases: WL = weight loss; OS = onset of signs; AP= acute paralysis; WG = weight gain; and PA = post-acute.

Example 2: Blood-brain Barrier Function

At various time points following EAE induction (Example 1), mice were injected intravenously with 2.5 x

-22-

10⁷ ⁵¹Cr-labelled lymph node cells and 5 µCi ¹²⁵I-albumin as described previously (Butter, C., et al., J. Neurol. Sci. 104:9 (1991)). Eighteen hours later anesthetized animals were perfused with RPMI-1640 medium, via the left
5 ventricle following the removal of a 20 µl blood sample. Brains and spinal cords of 4 - 14 animals per group were collected and estimations of the radioisotope concentrations were performed with a γ-spectrometer. The results are expressed as the number of donor cells per
10 gramme of target tissue and extravascular blood equivalents (EVBE), where 100 EVBE are equivalent to the ¹²⁵I-albumin plasma protein concentration in blood at the time of sampling, as described previously (Butter, C., et al., J. Neurol. Sci. 104:9 (1991)).

15 Figure 2 illustrates the blood-brain barrier permeability during acute phase chronic relapsing EAE. Open bars represent the permeability of the spinal cord to cells and hatched bars represent the permeability of the spinal cord to plasma protein. The results represent the
20 mean ± SEM of between 4-14 animals per group.

In normal (N) animals and up to day 11 post-inoculation following the induction of EAE, the central nervous system was relatively impermeable to trafficking of lymph node cells and plasma protein (Figure 2). Plasma
25 protein extravasation and cellular traffic both correlated with the development of clinical disease.

BBB breakdown was first detectable in the brain (data not shown), which is relatively uninvolved during EAE in AB/H mice (Baker, D., et al., J. Neuroimmunol. 28:261
30 (1990); (Butter, C., et al., J. Neurol. Sci. 104:9 (1991)), and the spinal cord (Figure 2) when animals

-23-

experienced weight loss. Blood-brain barrier permeability dramatically increased as clinical signs (OS and AP) developed and weight loss (a total of 25-35% of the body weight compared with day 12) progressed. Once weight gain became apparent in paralysed animals, BBB permeability markedly declined. Clinical signs abated during the post-acute phase and, as previously reported (Butter, C., et al., J. Neurol. Sci. 104:9 (1991)), the integrity of BBB was restored in remission animals. The results indicate that BBB dysfunction correlates with progressive weight changes.

Example 3: Detection of Tumour Necrosis Factor Activity

Tissue Fluids

Serum samples were prepared following exsanguination into the thoracic cavity, of terminally anesthetized animals during various phases of EAE. Cerebrospinal fluid (CSF) samples (1-3 μ l/animal) were withdrawn from foramen magnum into a haematocrit tube. Following centrifugation to remove cells, these samples were stored at -20°C prior to assay. Tumour necrosis activity was assessed using either the TNF-sensitive mouse fibroblast cell line L929, as described previously (Beutler B., Science 229:869 (1985)), or 1:2 dilutions of serum, and 1:50 dilutions of CSF were assayed using the Factor-Test mouse TNF α ELISA kit (Genzyme, UK), according to the manufacturer's instructions. The ELISA assay could detect 50 pg/ml - 3.2 ng/ml of TNF α .

Tissue sections

-24-

Acetone-fixed cryostat sections of cervical spinal cord were stained within 1 week of preparation by an indirect immunoperoxidase technique essentially as described previously (Baker, D., et al., J. Neuroimmunol. 5 28:261 (1990)). Briefly, endogenous peroxidase activity was blocked. Sections were incubated with 5% normal mouse serum (NMS) for 30 minutes followed by a 1 hour incubation with primary monoclonal antibody reactive with mouse TNF α / β , for example with TN3.19.12 monoclonal antibody, a 10 hamster immunoglobulin G1 (IgG1) monoclonal antibody which neutralizes mouse TNF α and TNF β (Sheehan, K.C.F., et al., J. Immunol. 142:3884 (1989)) (supplied by Dr. R. Schreiber, Washington University Medical School, St. Louis, USA in conjunction with Celltech, Slough, UK), or with primary 15 monoclonal antibody reactive with rat anti-mouse TNF α , for example with MP6-XT3 [HB10649] or MX6-XT22 [HB10697] both rat IgG1 monoclonal antibodies produced by hybridoma cell cultures (obtained from ATCC, courtesy of Dr. J. Abrams, DNAX, USA).

20 The primary monoclonal antibodies were detected by sequential 30 minute incubations with biotinylated goat anti-hamster immunoglobulin or rabbit anti-rat immunoglobulin, avidin:biotin peroxidase complex and peroxidase conjugated rabbit anti-goat immunoglobulin or 25 swine anti-rabbit immunoglobulin, respectively. The reaction product was developed using the chromogen diaminobenzidine. Sections were counterstained with haematoxylin. In some instances the primary monoclonal antibody was diluted with excess recombinant mouse TNF α 30 (200-500 μ g/ml) prior to use for immunocytochemistry.

-25-

This process failed to inhibit the staining of sections with a CD8-specific monoclonal antibody.

For double labelling, sections were incubated with rat anti-mouse TNF α , rabbit anti-rat immunoglobulin, and a 1:100 dilution (in phosphate buffered saline (PBS) containing 5% NMS) of swine anti-rabbit immunoglobulin which was conjugated with either tetra rhodamine isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC). Rabbit anti-Factor VIII-related antigen and rabbit anti-glial fibrillary acidic protein (GFAP) were conjugated with FITC and extensively dialyzed. Double immunofluorescence staining was then performed by incubating these sections with 1:50-1:100 dilutions (in 5% NMS) of either: FITC conjugated anti-Factor VIII, anti-GFAP, H-2A specific mouse monoclonal antibody, or phycoerythrin conjugated rat immunoglobulin monoclonal antibody specific for B cell restricted B220, CD4 or CD8 antigens for 30 minutes. Sections were observed by fluorescence microscopy.

20 Detection of TNF

The data shown in Figure 2 suggested that blood brain barrier dysfunction correlated with the weight loss of the animals. However, initial examination of sera from WL and AP animals, with the L929 cell line, failed to demonstrate the presence of biologically active TNF. Furthermore analysis of 5 individual samples of sera from WL, OS, AP and PA animals and CSF samples from 5 paralysed (AP) animals indicated that the level of TNF present was below the sensitivity of the TNF α ELISA assay used, indicating that at least in the serum samples, there was less than

-26-

100 pg/ml of TNF α . However, Figure 3 shows that it was possible to detect TNF within the central nervous system of chronic relapsing EAE animals using immunocytochemistry.

5 Although some TNF-specific monoclonal antibodies (MX6-XT22 [HB10649] and TN3.19.12) failed to produce satisfactory staining throughout a range of doses, suggesting that the tissue area which is recognized by these antibodies may be denatured, the TNF-specific
10 monoclonal antibody MP6-XT3 (20 μ l of 4-8 μ g/ml) revealed staining (Figure 3a) which was blocked by co-incubation of the monoclonal antibody with recombinant mouse TNF α (Figure 3b). Immunostaining demonstrated TNF α activity
15 within lesions present in the cervical spinal cord of paralysed animals (Figure 3a) and on some lesions of post-acute animals although the intensity of staining appeared reduced compared with that observed in paralysed (AP) animals.

 TNF α was present in mononuclear cells within
20 perivascular lesions and was often concentrated at the parenchyma/lesion edge where positive cells appeared macrophage/glial-like. Although some positive cells also appeared to have the morphology of astrocytes, the resolution of the immunoperoxidase stained tissue
25 precluded accurate identification of the cells expressing TNF.

 Figures 4a through 4h show the immunofluorescence detection of TNF α on CD4⁺ T lymphocytes, astrocytes and macrophages in spinal cord lesions during chronic
30 relapsing EAE. This distribution is similar to that observed in multiple sclerosis lesions (Hoffman, F.M., et

-27-

al., J. Exp. Med. 170:607 (1989); Selmaj, K., et al., J. Clin. Invest. 87:949 (1991)).

Tumour necrosis factor (TNF α) was detected by either FITC (Figure 4a) or TRITC (Figures 4c, 4e and 4g) conjugated antibody in the spinal cord lesions of
5 paralysed EAE animals. Sections were incubated with either a phycoerythrin conjugated CD4-specific monoclonal antibody (Figure 4b) or FITC conjugated Factor VIII related-antigen (Figure 4d), GFAP (Figure 4f) or H-2A-
10 specific antibodies (Figure 4h).

During the acute phase of chronic relapsing EAE both B cells and CD8 $^{+}$ T lymphocytes formed a minor component of the cellular infiltrate and B cells generally failed to show any evidence of TNF α activity by double
15 immunofluorescence staining. Occasionally some CD4 $^{+}$ T lymphocytes within perivascular lesions expressed TNF α (Figures 4a and 4b). The small arrows in Figure 4b indicate that some of the CD4 $^{+}$ T lymphocytes do not express the detectable TNF α activity of the CD4 $^{+}$ T
20 lymphocytes shown in Figure 4a, and the large arrows in Figures 4a and 4b indicate TNF α activity that is sometimes co-localized with cells expressing CD4 antigen.

Although TNF activity was detected in close proximity to blood vessels, staining typically failed to co-localize
25 with endothelial cells stained by anti-Factor VIII-related antigen (Figures 4c and 4d). The arrow in Figures 4c and 4d indicates the blood vessel within the perivascular lesion in the cells that do not co-express TNF α .

While some GFAP $^{+}$ astrocytes expressed TNF α (Figures
30 4e and 4f), particularly in areas adjacent to perivascular lesions, the majority of detectable TNF α activity co-

-28-

localized with macrophage/microglia cells expressing MHC class II antigens (Figures 4g and 4h).

The large arrows in Figures 4e and 4f indicate astrocytes expressing TNF α and the small arrows indicate astrocytes expressing TNF α localized to part of the astrocytic processes surrounding lesions. This astrocytic staining profile of TNF α is also depicted in Figures 4a, 4c and 4g. The arrow in Figures 4g and 4h indicates expression during EAE of TNF α within the central nervous system lesions.

Example 4: Oxazolone Proliferative Assay

Animals were painted on one ear with 25 μ l of 2.5% oxazolone (OX, Sigma, Poole, UK) dissolved in 4:1 acetone:olive oil (AOO) on day 0 (O'Neill, J.K., et al., J. Neuroimmunol. 35:53 (1992)). On day 2 the animals (3-4 per group) were injected intraperitoneally (i.p.) with 0.1 ml of TNF- or CD4-specific monoclonal antibodies diluted in PBS (500 μ g TN3.19.12, a TNF-specific monoclonal antibody, or approximately 250 μ g YTS 177.9, a rat IgG2a monoclonal antibody which is a non-depleting mouse CD4-specific antibody (Qin, S., et al., Eur. J. Immunol. 20:2737 (1990)) produced in ascites fluid.

Three days after the topical application of oxazolone, the draining auricular lymph nodes from each 3-4 animals per group were removed and pooled, and the induced proliferative response assessed as previously described (O'Neill, J.K., et al., J. Neuroimmunol. 35:53 (1992)). Briefly, 5×10^5 cells/well were cultured overnight (in the absence of exogenous oxazolone) at 37°C in a humidified atmosphere of 5% CO₂ in air with 2 μ Ci of

-29-

[methyl-³H] thymidine (specific activity 2 Ci/mmol). Cultures were harvested and [³H] thymidine incorporation was determined by β -scintillation counting.

Figure 7 shows the results of the effect of TNF immunotherapy on an in vivo induced T cell proliferative response from two individual experiments. The data depicted shows that in contrast to the immunosuppressive action of the CD4-specific antibody, the anti-TNF antibody did not inhibit T cell proliferative function under the conditions tested, indicating that these immunomodulatory compounds operate via different mechanisms. The results represent the mean \pm SD of a minimum of 5 replicate wells.

Example 5: Systemic anti-TNF Immunotherapy

To elucidate the potential role of TNF in a chronic relapsing EAE model, animals were injected with TN3.19.12, an anti-TNF monoclonal antibody. TN3.19.12 monoclonal antibody (supplied by Dr. R. Schreiber, Washington University Medical School, St. Louis, USA) has a serum half-life of approximately 7 days (Sheehan K.C.F., et al., J. Immunol. 142:3884 (1989)) and a single injection of 300 μ g of TN3.19.12 monoclonal antibody has been reported to inhibit the development of relapsing EAE induced by cell-transfer (Ruddle N.H., et al., J. Exp. Med. 172:1193 (1990)). However, a single intraperitoneal injection of 250 μ g of TN3.19.12 monoclonal antibody on day 12 post-inoculation following active sensitization failed to prevent animals (7 of 8) from developing EAE compared to those (8 of 8) injected with L2 3D9, a control non-neutralizing hamster IgG1 monoclonal antibody reactive with mouse interleukin-2 (supplied by Dr. R. Schreiber in

-30-

conjunction with Celltech, Slough, UK). However, there were reduced clinical manifestations (Figure 5).

Figure 5 illustrates the effect on EAE, specifically the effect on clinical signs, of a single injection of TNF-specific monoclonal antibody. The arrow indicates the day post-inoculation that the mice were injected intraperitoneally; the triangles represent the result from the mice that were injected intraperitoneally with 250 µg of TN3.19.12, a TNF-specific monoclonal antibody; and the inverse triangles represent the result from the mice that were injected intraperitoneally with 250 µg of L2 3D9, a control monoclonal antibody which is reactive with mouse interleukin-2. The results represent the mean clinical score of animals in each group \pm SEM, at various times post-inoculation.

Although the data obtained failed to reach statistical significance, the results nevertheless indicate that mice injected with TN3.19.12 monoclonal antibody, compared with mice injected with L2 3D9 monoclonal antibody, appear to exhibit a delayed onset of weight loss (day 16.1 ± 2.5 vs. 14.0 ± 0.9) and clinical signs (day 17.0 ± 2.0 vs. 15.4 ± 1.2) and a lower severity of maximum clinical signs (2.1 ± 1.1 vs. 3.1 ± 0.9) and body weight loss ($25.5 \pm 4.6\%$ vs. $29.0 \pm 4.8\%$). Furthermore, although animals which developed clinical disease following TN3.19.12 monoclonal antibody treatment subsequently relapsed, with 6 of 7 animals relapsing (day of onset 38.3 ± 7.5), control animals similarly relapsed, with 5 of 6 animals relapsing, on day 39.6 ± 5.3 when observed to day 55 post-inoculation.

-31-

Thus, TN3.19.12 monoclonal antibody administered just prior to the onset of clinical manifestations can partially inhibit the onset of EAE by 2-3 days. Therefore animals were given multiple (250 µg) antibody doses, 5 intraperitoneally at three-daily intervals (days 14, 17 and 20), initiated prior to and during the anticipated development of clinical disease (e.g., weight loss) (Table 1). In comparison to PBS and L2 3D9-treated controls, multiple doses of TNF-specific monoclonal antibody 10 significantly inhibited the development of EAE when assessed up to 3 days following the cessation of treatment. In the few instances where animals were injected when weight loss was first detected, TN3.19.12-treatment appeared to stabilize weight loss. However, as 15 shown in Table 1, although only 4 of 16 animals experienced clinical EAE during this period, within 10 days of monoclonal antibody treatment, the majority (13 of 16) of the animals subsequently developed clinical signs, although this represented a significant delay in the onset 20 of clinical signs. Although not significantly different from PBS-injected animals, L2 3D9-treatment appeared to reduce the severity of clinical signs expressed (Table 1).

TABLE 1
Multiple Doses of Systemically Administered TNF-Specific mAb
Inhibits the Development of EAE

Treatment	Results up to Day 23 p.i.		Results up to Day 30 p.i.		
	No. EAE/Total	Clinical Score	No. EAE/Total	Clinical Score	Day of Onset
PBS	13/15	2.6 ± 0.4	15/15	2.7 ± 0.4	17.7 ± 0.7
Hamster Ig (L2 3D9)	11/16	1.7 ± 0.4†	14/16	1.8 ± 0.4	18.4 ± 1.4†
anti-TNF TN3.19.12	4/16*	0.7 ± 0.3**	13/16	1.1 ± 0.3*	22.5 ± 0.7**

* P<0.01, ** P<0.002 compared with the PBS treated group.
† P<0.05 compared with the TNF-i.p. treated group.

-33-

Example 6: Systemic anti-TNF Immunotherapy after the Onset of Clinical Disease

SCH-immunized EAE animals were injected with TNF-specific monoclonal antibody when clinical signs were first manifested (day 0), that is when the animals were exhibiting a flaccid tail (grade 1). The mice were injected i.p. with 0.1 ml of either PBS, or 250 µg or 1 mg of TN3.19.12, a TNF-specific monoclonal antibody diluted in PBS, or 250 µg of L2 3D9, a hamster immunoglobulin monoclonal antibody diluted in PBS on days 0, 1 and 2 following the onset of clinical signs (Figure 6), or a single 250 µg injection i.p. of YTS 177.9, a CD4-specific monoclonal antibody diluted in PBS on day 0.

Figure 6 shows the inhibition of the development of clinical disease following the injection of a TNF-specific monoclonal antibody. The arrows indicate days on which the mice were injected i.p.; the circles represent the results from the mice that were injected i.p. with 0.1 ml of PBS; the triangles represent the results from the mice that were injected i.p. with TNF-specific antibody; the inverse triangles represent results from the mice that were injected i.p. with 250 µg L2 3D9 monoclonal antibody; and the diamonds represent the results from the mice that were injected i.p. with 250µg of YTS 177.9 monoclonal antibody on day 0.

Figure 6a shows the results following injection i.p. of 250 µg of a TNF-specific antibody. Figure 6b shows the results following injection i.p. of 1 mg of a TNF-specific antibody. The results represent the mean group clinical score \pm SEM (n=5-7) following the onset of signs.

-34-

Following the first injection of TN3.19.12 monoclonal antibody the clinical signs progressed (Figure 6). Antibody treatment was therefore continued daily for a further 2 days. Within 2 days of the onset of the administration of 250 µg of TN3.19.12 monoclonal antibody, clinical signs abated and were significantly different from the clinical signs observed in L2 3D9-treated animals, whose disease became more severe. However, L2 3D9-treated animals appeared to remit at a faster rate than PBS-treated animals, indicating that this non-neutralizing IL-2-specific antibody may be exhibiting some biological inhibitory effect (Figure 6a). Increasing the dose of TN3.19.12 monoclonal antibody administered to 1 mg failed to improve the inhibitory effect observed with administration of 250 µg TN3.19.12 monoclonal antibody (Figure 6b), although this significantly diminished the severity of clinical disease compared with PBS-treated animals.

In contrast, a non-depleting CD4-specific monoclonal antibody could rapidly stabilize and reverse clinical progression (Figure 6b). Although the mechanisms by which these antibodies act remain to be established, the observation that TNF-specific immunotherapy failed to inhibit an *in vivo* induced proliferative response whereas anti-CD4 treatment was markedly immunosuppressive (Figure 7) indicated that these mechanisms are different.

Example 7: Central Nervous System-directed TNF Immunotherapy

Following the onset of clinical signs, i.e., when the animals were exhibiting a flaccid tail (day 0), SCH-

-35-

immunized EAE mice were injected intracerebrally (i.c.) in the cortex of the right frontal lobe as previously described (O'Neill, J.K., *et al.*, J. Neuroimmunol. 35:53 (1992)) with varying doses of TN3.19.12 monoclonal antibody (Figure 8): 150 μ g, 15 μ g, 1.5 μ g, and 0 μ g. Although 1.5 μ g of TN3.19.12 monoclonal antibody failed to alter the clinical course of disease, 150 μ g of monoclonal antibody stabilized clinical disease (Figure 8).

Figure 8 thus shows the dose-dependent inhibition of the progression of clinical EAE following injection of TNF-specific monoclonal antibody directly into the central nervous system. The arrow indicates the onset of clinical signs when the animals were exhibiting a flaccid tail (day 0); the circles represent the results from the mice that were injected intracerebrally with 30 μ l of PBS; the inverse triangles represent results from the mice that were injected intracerebrally with 150 μ g TN3.19.12 monoclonal antibody; the triangles represent results from the mice which were injected intracerebrally with 15 μ g TN3.19.12 monoclonal antibody; and the diamonds represent results from the mice that were injected intracerebrally with 1.5 μ g of TNF-specific TN3.19.12 monoclonal antibody. The results represent the mean group score \pm SEM of 5 animals per group.

In additional experiments, following the onset of clinical signs, that is, when the animals were exhibiting a flaccid tail (day 0), SCH-immunized EAE mice were either untreated, or injected with 30 μ l of PBS i.c. and 150 μ g of TN3.19.12 monoclonal antibody i.p., or injected with 150 μ g of TN3.19.12 monoclonal antibody i.c. and 30 μ l of PBS i.p. (Figure 9). Intracerebral injection was in the

-36-

cortex of the right frontal lobe as previously described (O'Neill, J.K., et al., *J. Neuroimmunol.* 35:53 (1992)).

Figure 9 illustrates the inhibition of the development of more marked clinical disease following injection of TNF-specific monoclonal antibody directly into the central nervous system. The arrow indicates the treatment at onset of clinical signs when the animals were exhibiting a flaccid tail (day 0); the circles represent results from mice that were untreated; the triangles represent results from mice injected with 30 μ l of PBS i.c. and 150 μ g of TNF-specific monoclonal antibody i.p.; and the inverse triangles represent results from mice injected with 150 μ g of TNF-specific monoclonal antibody i.c. and 30 μ l of PBS i.p. (Figure 9). The mean clinical group score of 5-7 animals per group following the onset of clinical signs is shown.

The systemic i.p. injection of clinically-affected animals with 150 μ g of monoclonal antibody TN3.19.12 again initially failed to rapidly prevent the progression of disease (Figure 9). However, significant (double asterisk = $P < 0.002$; single asterisk = $P < 0.05$) benefit was observed when TNF immunotherapy (150 μ g monoclonal antibody) was administered directly into the central nervous system (Figure 9) compared to that administered systemically.

In contrast to the controls and to animals treated systemically with TN3.19.12 monoclonal antibody, where clinical signs always became more severe following disease onset, central nervous system-directed treatment generally stabilized clinical disease prior to remission, although in some cases animals experienced a transient increase in

-37-

severity of signs following a period of stabilization (Figure 10).

In another experiment, following the onset of clinical signs, SCH-immunized EAE mice were treated as follows: untreated; injected intraperitoneally with 250 μ g of YTS.177.9, a CD4-specific monoclonal antibody; injected intraperitoneally with 150 μ g TN3.19.12, a TNF-specific monoclonal antibody, and intracerebrally with 30 μ l of PBS; or injected intraperitoneally with 30 μ l of PBS and intracerebrally with 150 μ g of TN3.19.12 monoclonal antibody. As shown in Table 2, the results of this experiment indicate that intracerebral injection of TN3.19.12 monoclonal antibody significantly inhibited the progression of weight loss compared to both untreated animals and mice injected intraperitoneally with the TNF-specific antibody. In addition, although the majority of anti-TNF i.c.-treated animals (5 of 6) subsequently relapsed on day 35.6 ± 5.3 and the majority of the control animals (5 of 6) also relapsed on day 38.4 ± 3.4 , the results indicate that this treatment modulates the severity of clinical disease. The data thus indicate that although CD4⁺ cells can be targeted in the peripheral circulation prior to extravasation into the central nervous system, TNF-pathogenesis/activity/secretion occurs mainly in the central nervous system, and that appropriately administered TNF-specific immunotherapy into the central nervous system can inhibit the progression of neuroimmunological disease.

TABLE 2

Direct Administration of Anti-TNF Antibody Into the CNS Inhibits
Progressive Weight Loss During Clinical EAE Episodes

Treatment i.p.	none	anti-CD4	anti-TNF	PBS
Treatment i.c.	none	none	PBS	anti-TNF
Number Analyzed	20	10	12	13
Mean Weight at onset of treatment (g)	18.1 \pm 1.3	18.1 \pm 1.6	18.5 \pm 2.5	18.1 \pm 2.9
Mean Relative Weight Change 24 hours after treatment (g)	-1.37 \pm 0.11	+0.82 \pm 0.20*	-1.00 \pm 0.18*	-0.08 \pm 0.21*,†

* P<0.002 compared to untreated group.

† P<0.002 i.p. anti-TNF group compared with i.c. anti-TNF treatment group.

-39-

Example 8: Central Nervous System-directed Tumour
Necrosis Factor Receptor Immunotherapy

Following the onset of clinical signs, that is when the animals were exhibiting a flaccid tail (day 0), SCH-
5 immunized EAE mice were injected i.c. with 15 μ g of soluble human p55 SF2, a TNF receptor, or varying doses (0 μ g, 15 μ g, or 150 μ g) of TN3.19.12, a TNF-specific monoclonal antibody (Figure 11).

Figure 11 shows the inhibition of the development of
10 clinical disease following the injection of a TNF-specific monoclonal antibody and following the injection of a soluble human p55 TNF receptor. The arrow indicates the treatment at onset of clinical signs when the animals were exhibiting a flaccid tail (day 0); the circles represent
15 the results from the mice that were injected i.c. with 30 μ l of PBS; the triangles represent the results from the mice that were injected i.c. with 15 μ g of TNF-specific monoclonal antibody; the inverse triangles represent the results from the mice that were injected i.c. with 150 μ g
20 of TNF-specific monoclonal antibody; and the diamonds represent the results from the mice that were injected i.c. with 15 μ g of soluble human p55 TNF-R. The results represent the mean clinical score \pm SEM of 5-6 animals per group. The results observed when injecting i.c. with 15
25 μ g of soluble human p55 SF2 TNF-R is similar to the results observed when injecting i.c. with 150 μ g of anti-TNF monoclonal antibody, indicating, in this instance, the greater potency of the SF2 TNF-R.

-40-

Example 9: Systemic Tumour Necrosis Factor Receptor Immunotherapy

Following the onset of clinical signs, i.e., when the animals were exhibiting a flaccid tail (day 0), SCH-
5 immunized EAE mice were injected i.p. with varying doses of soluble human p55 sTNF-R (Figure 12): 150 µg, 15 µg and 0 µg.

Figure 12 shows the dose-dependent inhibition of the progression of clinical EAE following the injection of
10 soluble human p55 sTNF-R. The arrow indicates the treatment at onset of clinical signs when the animals were exhibiting a flaccid tail (day 0); the circles represent the results from the mice that were injected i.p. with 30 µl of PBS; the diamonds represent the results from the
15 mice that were injected i.p. with 15 µg of SF2 TNF-R; and the triangles represent the results from the mice that were injected i.p. with 150 µg of SF2 TNF-R. The results represent the mean clinical score ± SEM of 5-6 animals per group. The results show that the systemic effect of
20 soluble human p55 TNF receptor is at 15 - 150 µg/injection, and thus is more effective than the systemic effect of the TNF monoclonal antibody TN3.19.12.

Equivalents

Those skilled in the art will recognize, or be able
25 to ascertain using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

-41-

CLAIMS

1. A method of treating multiple sclerosis in a mammal, comprising administering to said mammal a therapeutically effective amount of an anti-tumour necrosis factor antibody which ameliorates the effects of multiple sclerosis.
2. A method of Claim 1 wherein the mammal is a human being.
3. A method of Claim 2 wherein the anti-tumour necrosis factor antibody is administered in a pharmaceutically-acceptable vehicle.
4. A method of Claim 2 wherein a therapeutically effective amount of an anti-tumour necrosis factor antibody is administered directly to the central nervous system of the human being.
5. A method of Claim 4 wherein the anti-tumour necrosis factor antibody is administered intrathecally.
6. A method of Claim 2 wherein the anti-tumour necrosis factor antibody is a polyclonal antibody.
7. A method of Claim 2 wherein the anti-tumour necrosis factor antibody is a monoclonal antibody.
8. A method of Claim 2 wherein the anti-tumour necrosis factor antibody is an antibody fragment.

-42-

9. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a multiple sclerosis-therapeutically effective amount of anti-tumour necrosis factor antibody which ameliorates the effects of multiple sclerosis.
5
10. A composition of Claim 9 wherein the anti-tumour necrosis factor antibody is a polyclonal antibody.
11. A composition of Claim 9 wherein the anti-tumour necrosis factor antibody is a monoclonal antibody.
- 10 12. A composition of Claim 9 wherein the anti-tumour necrosis factor antibody is an antibody fragment.
13. A method of treating multiple sclerosis in a mammal, comprising administering to said mammal a therapeutically effective amount of a soluble tumour necrosis factor receptor which ameliorates the effects of multiple sclerosis.
15
14. A method of Claim 13 wherein the mammal is a human being.
15. A method of Claim 14 wherein the soluble tumour necrosis factor receptor is administered in a pharmaceutically-acceptable vehicle.
20
16. A method of Claim 14 wherein a therapeutically effective amount of a soluble tumour necrosis factor

-43-

receptor is administered directly to the central nervous system.

17. A method of Claim 14 wherein the soluble tumour necrosis factor receptor is administered intrathecally.
18. A method of Claim 14 wherein the soluble tumour necrosis factor receptor is a binding fragment thereof.
19. A method of Claim 14 wherein the soluble tumour necrosis factor receptor is a soluble human p55-tumour necrosis factor receptor.
20. A method of Claim 19 wherein the soluble human p55-tumour necrosis factor receptor is a binding fragment thereof.
21. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a multiple sclerosis-therapeutically effective amount of soluble tumour necrosis factor receptor which ameliorates the effects of multiple sclerosis.
22. A composition of Claim 21 wherein the soluble tumour necrosis factor receptor is a binding portion thereof.

-44-

23. A composition of Claim 21 wherein the soluble tumour necrosis factor receptor is a soluble human p55-tumour necrosis factor receptor.
- 5 24. A composition of Claim 23 wherein the soluble human p55-tumour necrosis factor receptor is a binding portion thereof.
- 10 25. A method of treating multiple sclerosis in a human being, comprising administering directly to the central nervous system of said human being a therapeutically effective amount of an anti-tumour necrosis factor antibody.
- 15 26. A method of treating multiple sclerosis in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound capable of blocking tumour necrosis factor production, its effects and/or tumour necrosis factor receptor signal transduction.
- 20 27. Material capable of blocking: (1) the production or effects of tumour necrosis factor and/or (2) tumour necrosis factor receptor signal transduction, for use in therapy e.g. for treating multiple sclerosis.
- 25 28. Use of a material capable of blocking: (1) the production or effects of tumour necrosis factor and/or (2) tumour necrosis factor receptor signal transduction, for the manufacture of a medicament

-45-

for use in therapy, e.g. for treating multiple sclerosis.

- 5 29. Material according to claim 27 or the use according to claim 28, wherein the material comprises a composition according to any one of claims 9-12 or 21-24.
- 10 30. Material or use according to any one of claims 27-29, wherein the therapy comprises a method according to any one of claims 1-8, 13-20 or 25-26.

1/14

FIGURE 1




FIGURE 2




Figure 3

a



b





Figure 4

a



b





Figure 4

c



d





Figure 4

e



f






Figure 4

g




h



7/14

FIGURE 5



8/14

Figure 6a







Figure 6b



SUBSTITUTE SHEET

9/14

FIGURE 7



SUBSTITUTE SHEET

10/14

FIGURE 8




FIGURE 9




FIGURE 10






FIGURE 11





FIGURE 12



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/01614

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/395 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	--/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

31 March 1994

Date of mailing of the international search report

27 -04- 1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

Inter. natl Application No

PCT/GB 93/01614

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>THE JOURNAL OF EXPERIMENTAL MEDICINE vol. 172, no. 4 , 1 October 1990 , NEW YORK, USA pages 1193 - 1200 N. RUDDLE ET AL. 'An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis.' cited in the application see abstract see page 1194, right column, line 13 - line 21 see page 1195, right column, line 4 - line 13 see page 1195, right column, line 21 - line 32 see page 1196, left column, line 7 - page 1198, left column, line 8 see table 2</p>	1,9-11, 26-30
X	<p>ANNALS OF NEUROLOGY vol. 30, no. 5 , November 1991 , BOSTON MA, USA pages 694 - 700 K. SELMAJ ET AL. 'Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.' cited in the application see abstract</p>	1,9-11, 26-30
X	<p>CURRENT OPINION IN IMMUNOLOGY vol. 4, no. 6 , December 1992 , LONDON, GB pages 754 - 759 F. BRENNAN ET AL. 'Cytokines in autoimmunity.' see page 755, left column, line 40 - right column, line 29 see page 756, right column, line 14 - line 37</p>	1,9-11, 13, 21-24, 26-30
X	<p>EP,A,0 512 528 (YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.) 11 November 1992 see page 2, line 26 - line 30 see example 2 see claim 9</p>	26-28
X	<p>DE,A,42 02 665 (SCHERING BERLIN & BERGKAMEN AG) 29 July 1993 see the whole document</p>	26-28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB93/01614

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark : Although claims 1-8, 13-20, 25 and 26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/GB 93/01614

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0512528	11-11-92	AU-A- 1609492	12-11-92
		CA-A- 2068027	08-11-92
		JP-A- 5170661	09-07-93
DE-A-4202665	29-07-93	WO-A- 9314761	05-08-93